Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia
HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms…
HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms…
SINGAPORE, Jul 3, 2023 – (ACN Newswire) – SMI Vantage Limited, a company listed on…
SEOUL, South Korea–(BUSINESS WIRE)–#Autosilicon–Following the mass production of its ASIL-D certified Battery Management IC chipset…
My Tooth Media has expanded their digital market services, now offering better services for dental…
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulation…
PACIFIC GROVE, Calif.–(BUSINESS WIRE)–California American Water‘s Aquifer Storage and Recovery (ASR) program captured excess winter…
Sky Elements Drone Shows, a company that specializes in aerial entertainment, has announced show design…
Ads Up Marketing launches resources to enhance drug rehab marketing, SEO for rehab owners, and…
Move Affirms Lobe’s Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to…